HC Wainwright Predicts Higher Earnings for Beam Therapeutics

Beam Therapeutics Inc. (NASDAQ:BEAM) – Equities researchers at HC Wainwright increased their Q2 2025 earnings per share (EPS) estimates for shares of Beam Therapeutics in a note issued to investors on Wednesday, May 7th. HC Wainwright analyst P. Trucchio now anticipates that the company will earn ($0.78) per share for the quarter, up from their previous estimate of ($0.94). HC Wainwright currently has a “Buy” rating and a $80.00 target price on the stock. The consensus estimate for Beam Therapeutics’ current full-year earnings is ($4.57) per share. HC Wainwright also issued estimates for Beam Therapeutics’ Q3 2025 earnings at ($0.78) EPS, Q4 2025 earnings at ($0.79) EPS, FY2025 earnings at ($3.54) EPS, Q1 2026 earnings at ($0.75) EPS, Q2 2026 earnings at ($0.76) EPS, Q3 2026 earnings at ($0.76) EPS, Q4 2026 earnings at ($0.74) EPS, FY2026 earnings at ($3.00) EPS, FY2027 earnings at ($2.75) EPS, FY2028 earnings at ($1.77) EPS and FY2029 earnings at ($1.34) EPS.

Several other analysts have also weighed in on BEAM. Guggenheim dropped their price objective on shares of Beam Therapeutics from $78.00 to $55.00 and set a “buy” rating for the company in a report on Wednesday, May 7th. Wedbush reaffirmed an “outperform” rating and set a $57.00 price target on shares of Beam Therapeutics in a report on Monday, March 10th. Cantor Fitzgerald reissued an “overweight” rating on shares of Beam Therapeutics in a research note on Wednesday, March 12th. Wells Fargo & Company decreased their target price on Beam Therapeutics from $75.00 to $70.00 and set an “overweight” rating on the stock in a report on Wednesday, May 7th. Finally, Bank of America raised Beam Therapeutics from a “neutral” rating to a “buy” rating and set a $42.00 price target for the company in a report on Friday, March 28th. Two equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, Beam Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $48.75.

Beam Therapeutics Stock Down 1.0%

Shares of BEAM stock opened at $18.05 on Monday. The company has a market capitalization of $1.82 billion, a P/E ratio of -10.26 and a beta of 2.35. Beam Therapeutics has a 12-month low of $13.53 and a 12-month high of $35.25. The firm has a 50-day moving average price of $19.92 and a 200 day moving average price of $24.33.

Beam Therapeutics (NASDAQ:BEAM) last announced its quarterly earnings results on Tuesday, May 6th. The company reported ($1.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.11) by ($0.13). The company had revenue of $7.47 million during the quarter, compared to the consensus estimate of $14.69 million. Beam Therapeutics had a negative net margin of 41.07% and a negative return on equity of 16.22%. The business’s revenue was up 1.4% on a year-over-year basis. During the same quarter last year, the company earned ($1.21) earnings per share.

Institutional Trading of Beam Therapeutics

A number of large investors have recently made changes to their positions in the company. Horizon Kinetics Asset Management LLC lifted its holdings in Beam Therapeutics by 4.4% during the fourth quarter. Horizon Kinetics Asset Management LLC now owns 9,597 shares of the company’s stock worth $238,000 after acquiring an additional 403 shares in the last quarter. Summit Investment Advisors Inc. raised its position in shares of Beam Therapeutics by 6.6% during the fourth quarter. Summit Investment Advisors Inc. now owns 7,999 shares of the company’s stock worth $198,000 after purchasing an additional 496 shares during the period. Amalgamated Bank lifted its holdings in shares of Beam Therapeutics by 20.4% during the 1st quarter. Amalgamated Bank now owns 3,153 shares of the company’s stock valued at $62,000 after purchasing an additional 534 shares in the last quarter. Avanza Fonder AB grew its position in shares of Beam Therapeutics by 1.6% in the 1st quarter. Avanza Fonder AB now owns 51,077 shares of the company’s stock valued at $944,000 after purchasing an additional 792 shares during the period. Finally, Mitsubishi UFJ Asset Management Co. Ltd. grew its position in shares of Beam Therapeutics by 9.1% in the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 10,492 shares of the company’s stock valued at $205,000 after purchasing an additional 879 shares during the period. Institutional investors own 99.68% of the company’s stock.

Insider Buying and Selling

In related news, insider Christine Bellon sold 5,674 shares of Beam Therapeutics stock in a transaction that occurred on Tuesday, April 1st. The shares were sold at an average price of $18.35, for a total transaction of $104,117.90. Following the transaction, the insider now owns 117,294 shares of the company’s stock, valued at $2,152,344.90. This trade represents a 4.61% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, President Giuseppe Ciaramella sold 7,434 shares of the company’s stock in a transaction that occurred on Tuesday, April 1st. The shares were sold at an average price of $18.35, for a total transaction of $136,413.90. Following the completion of the sale, the president now directly owns 190,216 shares of the company’s stock, valued at $3,490,463.60. The trade was a 3.76% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 43,771 shares of company stock valued at $803,198 over the last three months. Company insiders own 4.20% of the company’s stock.

About Beam Therapeutics

Beam Therapeutics Inc, a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a.